SEC Form 4 · accession 0001179110-15-007641
ABIOMED INC · ABMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew J Greenfield
Officer — VP Healthcare Solutions
Period of report
May 8, 2015
Accepted (ET)
May 12, 2015 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000815094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par value | May 8, 2015 | M | 22,881 | $13.57 | A | 91,619 | D | |
| Common Stock, $.01 par valueF5,F6 | May 8, 2015 | S | 4,322 | $64.1598 | D | 87,297 | D | |
| Common Stock, $.01 par valueF5,F7 | May 8, 2015 | S | 4,852 | $65.1294 | D | 82,445 | D | |
| Common Stock, $.01 par valueF5,F8 | May 8, 2015 | S | 2,549 | $66.3304 | D | 79,896 | D | |
| Common Stock, $.01 par valueF5,F9 | May 8, 2015 | S | 6,506 | $67.3335 | D | 73,390 | D | |
| Common Stock, $.01 par valueF5,F10 | May 8, 2015 | S | 3,685 | $67.8776 | D | 69,705 | D | |
| Common Stock, $.01 par valueF5,F11 | May 8, 2015 | S | 870 | $69.0306 | D | 68,835 | D | |
| Common Stock, $.01 par valueF5,F12 | May 8, 2015 | S | 97 | $69.81 | D | 68,738 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.57 | May 8, 2015 | M | 22,881 | D | Jun 1, 2007 | Jun 1, 2016 | Common Stock | 22,881 | 0 | D |
| Stock Option (right to buy)F1,F2 | $11.27 | holding | — | — | — | May 30, 2008 | May 30, 2017 | Common Stock | 0 | 10,000 | D |
| Stock Option (right to buy)F1,F2 | $13.80 | holding | — | — | — | May 23, 2009 | May 23, 2018 | Common Stock | 0 | 9,000 | D |
| Stock Option (right to buy)F3,F2 | $10.03 | holding | — | — | — | Jun 3, 2011 | Jun 3, 2020 | Common Stock | 0 | 25,000 | D |
| Stock Option (right to buy)F3,F2 | $22.44 | holding | — | — | — | May 22, 2013 | May 22, 2022 | Common Stock | 0 | 20,000 | D |
| Stock Option (right to buy)F3,F2 | $14.39 | holding | — | — | — | Feb 19, 2014 | Feb 19, 2023 | Common Stock | 0 | 20,000 | D |
| Stock Option (Right to Buy)F3,F2 | $23.15 | holding | — | — | — | May 14, 2014 | May 14, 2023 | Common Stock | 0 | 20,000 | D |
| Stock Option (right to buy)F3,F4 | $21.55 | holding | — | — | — | May 14, 2015 | May 14, 2024 | Common Stock | 0 | 15,000 | D |
Explanation of responses
- F1Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2000 Stock Incentive Plan.
- F10This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $67.7000 and $68.66000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F11This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $68.7000 and $69.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F12This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $69.7000 and $69.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F2These options became exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- F3Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2008 Stock Incentive Plan.
- F4These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- F5Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- F6This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $63.6200 and $64.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F7This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $64.6200 and $65.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F8This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $65.6750 and $66.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- F9This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $66.7000 and $67.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.